AllianceBernstein’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-492,486
Closed -$18.6M 3535
2021
Q1
$18.6M Buy
492,486
+426,686
+648% +$10.6M 0.01% 954
2020
Q4
$1.12M Sell
65,800
-9,300
-12% -$117K ﹤0.01% 2244
2020
Q3
$353K Hold
75,100
﹤0.01% 2723
2020
Q2
$458K Buy
75,100
+11,500
+18% +$47.4K ﹤0.01% 2673
2020
Q1
$144K Buy
63,600
+3,700
+6% +$15.7K ﹤0.01% 2887
2019
Q4
$275K Sell
59,900
-500
-0.8% -$1.98K ﹤0.01% 2811
2019
Q3
$234K Hold
60,400
﹤0.01% 2888
2019
Q2
$364K Buy
60,400
+10,500
+21% +$100K ﹤0.01% 2746
2019
Q1
$669K Sell
49,900
-155,900
-76% -$1.78M ﹤0.01% 2418
2018
Q4
$1.91M Buy
205,800
+155,900
+312% +$1.86M ﹤0.01% 1852
2018
Q3
$695K Hold
49,900
﹤0.01% 2487
2018
Q2
$789K Buy
49,900
+2,880
+6% +$50.3K ﹤0.01% 2420
2018
Q1
$808K Buy
47,020
+820
+2% +$16K ﹤0.01% 2354
2017
Q4
$1.01M Hold
46,200
﹤0.01% 2260
2017
Q3
$1.89M Hold
46,200
﹤0.01% 1883
2017
Q2
$1.39M Sell
46,200
-51,570
-53% -$1.61M ﹤0.01% 2108
2017
Q1
$3.53M Buy
97,770
+8,220
+9% +$362K ﹤0.01% 1408
2016
Q4
$4.49M Sell
89,550
-18,200
-17% -$956K ﹤0.01% 1258
2016
Q3
$5.66M Buy
107,750
+24,250
+29% +$1.16M ﹤0.01% 1074
2016
Q2
$3.45M Buy
83,500
+48,760
+140% +$2.12M ﹤0.01% 1265
2016
Q1
$1.41M Buy
34,740
+7,340
+27% +$252K ﹤0.01% 1877
2015
Q4
$1.14M Buy
27,400
+8,600
+46% +$288K ﹤0.01% 2049
2015
Q3
$289K Buy
18,800
+3,300
+21% +$70.9K ﹤0.01% 2671
2015
Q2
$385K Buy
15,500
+7,500
+94% +$167K ﹤0.01% 2678
2015
Q1
$183K Buy
8,000
+6,800
+567% +$172K ﹤0.01% 2865
2014
Q4
$32K Hold
1,200
﹤0.01% 3162
2014
Q3
$14K Sell
1,200
-1,200
-50% -$15.1K ﹤0.01% 3247
2014
Q2
$37K Buy
+2,400
New +$34.4K ﹤0.01% 3155

AllianceBernstein's FPRX Position: Q2 2021 in Review

AllianceBernstein sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 492,486 shares — an estimated $18.6M sold.

AllianceBernstein first reported a position in FPRX in Q2 2014 and held it in 28 quarters. The position peaked at $18.6M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • AllianceBernstein reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • AllianceBernstein sold 492,486 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $18.6M.
  • AllianceBernstein first reported a position in Five Prime Therapeutics, Inc. in Q2 2014 and held it in 28 quarters.
  • AllianceBernstein's Five Prime Therapeutics, Inc. position peaked at $18.6M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.